A fresh study published in JAMA shows that measuring apolipoprotein B (ApoB) prevents more heart attacks and strokes than relying on LDL cholesterol alone.
Why ApoB testing identifies higher risk than standard cholesterol tests
Standard blood tests measure the amount of fat in lipoprotein particles but not how many dangerous particles are actually circulating in the bloodstream. ApoB sits on each harmful particle — including LDL, VLDL, and IDL — and directly counts them. Two people with identical LDL levels can have vastly different cardiovascular risk depending on the actual number of these particles.

How the simulation compared treatment strategies for 250,000 adults
Researchers at Northwestern University modeled three approaches in 250,000 U.S. Adults without prior heart disease: treatment guided by LDL, non-HDL cholesterol, and ApoB levels. The ApoB-guided strategy prevented the most cardiovascular events, demonstrating superior predictive power for prevention.
What this means for current prevention guidelines and patient screening
If adopted, ApoB testing could redefine who qualifies for preventive therapies like statins, shifting focus from fat concentration to particle count. This change may reduce missed cases where standard tests underestimate risk despite normal LDL readings.

What is ApoB and why is it better than LDL for predicting heart risk?
ApoB is a protein found on each harmful lipoprotein particle, allowing direct count of circulating LDL, VLDL, and IDL particles. Unlike LDL cholesterol, which measures fat content, ApoB reflects the actual number of particles that can penetrate artery walls and drive plaque buildup.
Will ApoB testing replace LDL testing in routine checkups soon?
The study does not claim ApoB will replace LDL testing, but suggests it offers a more complete risk assessment. Adoption would depend on clinical guidelines, cost, and availability — factors not addressed in the research.